Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/8747
Title: Mesenchymal stem cell-dependent modulation of liver diseases
Authors: Gazdic, Marina
Arsenijevic A.
Markovic B.
Volarevic, Ana
Dimova I.
Djonov V.
Arsenijevic, Nebojsa
Stojkovíc M.
Volarevic, Vladislav
Journal: International Journal of Biological Sciences
Issue Date: 5-Sep-2017
Abstract: © Ivyspring International Publisher. Acute liver failure and cirrhosis display sequential and overlapping severe pathogenic processes that include inflammation, hepatocyte necrosis, and fibrosis, carrying a high mortality rate. Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal stem cells with immunonodulatory characteristics. MSCs are considered to act through multiple mechanisms to coordinate a dynamic, integrated response to liver inflammation and fibrosis, which prevents the progressive distortion of hepatic architecture. Accordingly, MSCs as well as their products have been investigated as a novel therapeutic approach for the treatment of inflammatory and fibrotic liver diseases. In this review, we highlight the current findings on the MSC-based modulation of liver inflammation and fibrosis, and the possible use of MSCs in the therapy of immune-mediated liver pathology. We briefly describe the cellular and molecular mechanisms involved in MSC-dependent modulation of cytokine production, phenotype and function of liver infiltrated inflammatory cells and compare effects of engrafted MSCs versus MSC-generated conditioned medium (MSC-CM) in the therapy of acute liver injury. In order to elucidate therapeutic potential of MSCs and their products in modulation of chronic liver inflammation and fibrosis, we present the current findings regarding pathogenic role of immune cells in liver fibrosis and describe mechanisms involved in MSC-dependent modulation of chronic liver inflammation with the brief overview of on-going and already published clinical trials that used MSCs for the treatment of immune mediated chronic liver diseases. The accumulating evidence shows that MSCs had a significant beneficial effect in the treatment of immune-mediated liver diseases.
URI: https://scidar.kg.ac.rs/handle/123456789/8747
Type: Review
DOI: 10.7150/ijbs.20240
ISSN: 14492288
SCOPUS: 85029171034
Appears in Collections:Faculty of Medical Sciences, Kragujevac
[ Google Scholar ]

Page views(s)

14

Files in This Item:
File Description SizeFormat 
10.7150-ijbs.20240.pdf686.9 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.